Human immunodeficiency virus reservoir might be actively eradicated as residual malignant cells by cytotoxic chemotherapy

Medical Hypotheses

Volumn 62, Issue 3, 2004, Pages 358-363

  Yang, Quan En ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GENOMIC DNA; HYDROXYUREA; IMMUNOTOXIN; INTERLEUKIN 2; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PEPTIDE NUCLEIC ACID; PROTEINASE INHIBITOR; PURINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIOGUANINE; VIRUS RNA; ZIDOVUDINE;

ACUTE LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CYTOTOXICITY; DNA REPLICATION; ERADICATION THERAPY; GENE TRANSFER; GENE VECTOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LEUKOPENIA; LONG TERM CARE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RESERVOIR; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VIREMIA; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

DIGITAL PRODUCTS; INTELLIGENCE RIGHTS; LEGISLATIVE COPYRIGHTS; PUBLIC RIGHTS;

COMPACT DISKS; COMPUTER SOFTWARE; ELECTRONIC COMMERCE; INFORMATION TECHNOLOGY; INFORMATION USE; INTERNET; LAWS AND LEGISLATION; MANAGEMENT INFORMATION SYSTEMS; ONLINE SYSTEMS;

COPYRIGHTS;

EID: 14244249872     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.10.012     Document Type: Article

References (39)

1. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
2. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
3. Persaud D, Pierson T, Ruff C, et al. A stable reservoir for HIV-1 in resting CD4 (+) T lymphocytes in infected children. J Clin Inves 2000;105:995-1003.
4. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication- competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
5. Hanly A, Petito CK. HLA·DR-positive dendritic cells of the normal human choroids plexus: a potential reservoir of HIV in the central nerve system. Hum Pathol 1998;29:88-93.
6. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339:1803-9.
7. Chun TW, Davey Jr RT, Engel D, Lane HC, Fauci AS. Reemergence of HIV after stopping therapy. Nature 1999; 401:874-5.
8. Cohen OJ, Fauci AS. Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable. Lancet 1999;354: 697-8.
9. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-5.
10. Wang D, de la Fuente C, Deng L, et al. Inhibition of human immunodeficiency virus type-1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 2001;75: 7266-79.
11. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-5.
12. Saavedra-Lozano J, McCoig C, Xu J, et al. An Anti-CD45RO immunotoxin kills latently infected Human Immunodeficiency Virus (HIV) CD4 T cells in the blood of HIV-positive persons. J Inf Dis 2002;185:306-14.
13. Dillman RO. Monoclonal antibody therapy for lymphoma: an update. Cancer Pract 2001;9:71-80.
14. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-1 infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999; 5:29-33.
15. Agarwal S, Ikeuchi T, Sun D, et al. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodideoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci USA 1989;86:7790-4.
16. Sei S, Yang Q, O'Neill D, et al. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol 2000;74:4621-33.
17. Gaynon PS. Primary treatment of childhood acute lymphoblastic leukemia of non-T cell lineage including infants. Hematol/Oncol Clin NA 1990;4:915-36.
18. Hoelzer DF, Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol/Oncol Clin NA 1993;7:139-60.
19. Pui CH, Evans WE. Drug therapy: acute lymphoblastic leukemia. N Engl J Med 1998;339:605-15.
20. Nilsson A, De Milito A, Engström Pär, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002;109:e91.
21. Contu L, La Nasa G, Arras M, et al. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant 1993;12: 669-71.
22. Holland HK, Saral R, Rossi JJ, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type-1 (HIV-1) infection. Ann Int Med 1989;111:973-81.
23. + peripheral blood progenitor cells transplantation in an HIV/HCV co-infected patient with acute myeloid leukemia. Exp Hematol 2002;30:279-84.
24. Smith C, Lilly S, Miralles GD. Treatment of HIV infection with cytoreductive agents. AIDS Res Hum Retroviruses 1998;14:1305-13.
25. Simard C, Jolicoeur P. The effect of anti-neoplastic drugs on murine acquired immunodeficiency syndrome. Science 1991;251:305-8.
26. Yang Q, Li K, Mikovits JA. Eradication of HIV-1 infected cells by combination of antimetabolic cytotoxic chemotherapy and antiviral chemotherapy in vitro: A pilot study. J Inf Dis 2002;186:706-9.
27. Patel PH, Preston BD. Marked infidelity of human immunodeficiency virus type 1 reverse transcriptase at RNA and DNA template ends. Proc Natl Acad Sci USA 1994;91: 549-53.
28. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 1998;338:853-60.
29. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretrovral therapy. JAMA 1998;279:450-4.
30. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-8.
31. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Eng J Med 1999;278: 1291-5.
32. Lori F, Malykh A, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type-1 resistance. AIDS Res Hum Retrovir 1997;13:1403-9.
33. Ravot E, Lisziewicz J, Lori F. New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporine and thalidomide. Drug 1999;58:953-63.
34. Bartlett JA, Miralles GD, Sevin AD, et al. Addition of cyclophosphamide to antiretroviral therapy does not dimish the cellular reservoir in HIV-infected persons. AIDS Res Hum Retrovir 2002;18:535-43.
35. Elion GB. The purine path to chemotherapy. Science 1989;244:41-7.
36. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990;336: 225-9.
37. Adamson PC, Poplack DG, Balis FM, et al. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 1994;11:805-10.
38. Steinberg AD, Plotz PH, Wolff SM, Wong VG, Agus SG, Decker JL. Cytotoxic drugs in treatment of nonmalignant diseases. Ann Intern Med 1992;76:619-42.
39. Kulkosky J, Pomerantz RJ. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type-1 reservoirs with immune activation therapy. CID 2002;35:1520-6.